trial · primary record
Indoximod
Ependymoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2029-12-28 |
| Primary endpoint | Incidence of regimen-limiting toxicity (RLT) for Regimen A |
| Registry ID | NCT05106296 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:55.930Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05106296
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Indoximod · compound